Axial Spondyloarthritis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Axial Spondyloarthritis - Pipeline Review, H1 2016', provides an overview of the Axial Spondyloarthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis - The report reviews pipeline therapeutics for Axial Spondyloarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Axial Spondyloarthritis therapeutics and enlists all their major and minor projects - The report assesses Axial Spondyloarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Axial Spondyloarthritis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Axial Spondyloarthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Axial Spondyloarthritis Overview 6 Therapeutics Development 7 Pipeline Products for Axial Spondyloarthritis - Overview 7 Axial Spondyloarthritis - Therapeutics under Development by Companies 8 Axial Spondyloarthritis - Pipeline Products Glance 9 Late Stage Products 9 Early Stage Products 10 Axial Spondyloarthritis - Products under Development by Companies 11 Axial Spondyloarthritis - Companies Involved in Therapeutics Development 12 AbbVie Inc. 12 Eli Lilly and Company 13 Johnson & Johnson 14 Novartis AG 15 Sandoz International GmbH 16 UCB S.A. 17 Xbrane Biopharma AB 18 Axial Spondyloarthritis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 adalimumab - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 certolizumab pegol - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 certolizumab pegol biosimilar - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 etanercept biosimilar - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 etanercept biosimilar - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ixekizumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 secukinumab - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ustekinumab - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Axial Spondyloarthritis - Recent Pipeline Updates 55 Axial Spondyloarthritis - Dormant Projects 88 Axial Spondyloarthritis - Product Development Milestones 89 Featured News & Press Releases 89 Jan 16, 2016: BENEPALI. the First Etanercept Biosimilar Referencing Enbrel, Approved in the European Union 89 Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting 89 Sep 08, 2015: Merck and Samsung Bioepis Announce Approval of BRENZYS (Etanercept), a Biosimilar of Enbrel, in Korea 94 Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting 94 Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis 98 Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 99 Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study 100 Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis 102 Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting 103 Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting 104 Appendix 107 Methodology 107 Coverage 107 Secondary Research 107 Primary Research 107 Expert Panel Validation 107 Contact Us 107 Disclaimer 108
List of Tables
Number of Products under Development for Axial Spondyloarthritis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Axial Spondyloarthritis - Pipeline by AbbVie Inc., H1 2016 12 Axial Spondyloarthritis - Pipeline by Eli Lilly and Company, H1 2016 13 Axial Spondyloarthritis - Pipeline by Johnson & Johnson, H1 2016 14 Axial Spondyloarthritis - Pipeline by Novartis AG, H1 2016 15 Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H1 2016 16 Axial Spondyloarthritis - Pipeline by UCB S.A., H1 2016 17 Axial Spondyloarthritis - Pipeline by Xbrane Biopharma AB, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Axial Spondyloarthritis Therapeutics - Recent Pipeline Updates, H1 2016 55 Axial Spondyloarthritis - Dormant Projects, H1 2016 88
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.